

NARINE JEENARINE
Form 4
April 30, 2013

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
NARINE JEENARINE

2. Issuer Name and Ticker or Trading Symbol
ELITE PHARMACEUTICALS INC
/NV/ [eltp]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
04/25/2013

Director 10% Owner
 Officer (give title below) Other (specify below)

C/O EPIC PHARMA, LLC, 227-15
NORTH CONDUIT AVENUE

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

LAURELTON, NY 11413

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/25/2013		D		150,000	D	\$ 0.08
							16,412,461 (2)
						I (1)	see footnote (1)
Common Stock	04/26/2013		D		243,926	D	\$ 0.0802
							16,168,535 (3)
						I (1)	see footnote (1)
Common Stock	04/26/2013		C(7)		8,230,453	A	\$ 0 (7)
							24,398,988 (4)
						I (1)	see footnote (1)
Common	04/29/2013		D		130,000	D	\$ 0.08
							24,268,988
						I (1)	see

Edgar Filing: NARINE JEENARINE - Form 4

Stock						<u>(5)</u>		footnote <u>(1)</u>
Common Stock	04/29/2013		<u>J(8)</u>	13,367,481	D	\$ 0.0369	15,357,334 <u>(6)</u>	I <u>(1)</u> see footnote <u>(1)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Underlying Security (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title
Series E Convertible Preferred Stock	\$ 0.0243	04/26/2013		C	200	04/26/2013	<u>(10)</u>	Common Stock
Warrants	\$ 0.0625	04/26/2013		<u>J(9)</u>	13,272,999	10/30/2009	10/30/2016	Common Stock

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
NARINE JEENARINE C/O EPIC PHARMA, LLC 227-15 NORTH CONDUIT AVENUE LAURELTON, NY 11413	X	X		

Signatures

Jeenarine Narine 04/29/2013

 **Signature of Reporting Person

____ Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Jeenarine Narine is an equity owner and executive officer of each of Epic Pharma, LLC ("EP"), and Epic Investments, LLC ("EI") (which is controlled by EP), which owns securities convertible into or exercisable for in excess of 10% of the outstanding shares of common stock of the issuer, and also serves as a director of the issuer.
- (1) Of the 16,412,461 shares of common stock, 14,910,666 shares of common stock are owned indirectly through EI and 1,501,795 shares are owned directly by the reporting person.
 - (2) Of the 16,168,535 shares of common stock, 14,666,740 shares of common stock are owned indirectly through EI and 1,501,795 shares are owned directly by the reporting person
 - (3) Of the 24,398,988 shares of common stock, 22,897,193 shares of common stock are owned indirectly through EI and 1,501,795 shares are owned directly by the reporting person
 - (4) Of the 24,268,988 shares of common stock, 22,767,193 shares of common stock are owned indirectly through EI and 1,501,795 shares are owned directly by the reporting person
 - (5) Of the 15,357,334 shares of common stock, 9,399,712 shares of common stock are owned indirectly through EI and 1,501,795 shares are owned directly by the reporting person
 - (6) Conversion of Series E Preferred Stock of issuer at the rate of approximately 41,152.26 shares of common for each share of such preferred stock.
 - (7) Disposition of shares to its members
 - (8) Disposition of warrants to its members
 - (9) N/A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.